The reasons people hate drug ads on TV; FDA's Califf on the Aduhelm congressional report

We looked at the complaints people lodge with the FCC about prescription drug ads. Most focused on one of four issues. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: People hate drug ads on TV. Here's the 4 issues they complain about most By Kate Sheridan Molly Ferguson for STAT We looked at the complaints people have lodged with the FCC about prescription drug ads. Most focused on one of four issues. Read More Mistakes happen in research papers. But corrections often don't By Ambar Castillo Adobe A culture of fear around corrections and retractions is hampering efforts to maintain the integrity of scientific research. Read More STAT+: FDA's Califf says congressional report on Aduhelm controversy contained 'no surprises' By Jonathan Wosen STAT FDA head Robert Califf made his first public comments following a congressional investigation into the agency’s role in approving Aduhelm. Read More Sponsored Insight by Altera Digital Health Acceleration vs. Evolution: An iterative approach to personalizing digital experiences for healthcare providers Healthcare technology platforms of health should adapt to people, not the other way around. Leaders must listen to what their end-users are saying about how technology helps (or hinders) their ability to work at the top of their license. The digitization of healthcare should be an evolution, not just an acceleration. Learn more about Altera Health's iterative approach to personalizing digital experiences for healthcare providers. STAT+: An FDA pathway to clear medical devices is putting patients at risk, research suggests By Matthew Herper Adobe New research examines medical devices cleared through the FDA's 510(k) pathway based on existing devices that have had a recall. Read More With attention to mpox fading, health officials fear infections will go undetected and unreported By Helen Branswell ERNESTO BENAVIDES/AFP via Getty Images The explosive period of the outbreak is now over, but the outbreak itself is not, said the WHO's point person on poxviruses. Read More Opinion: Is the golden age of biotech stocks over? By Nathan Vardi Adobe New political, regulatory, and structural obstacles may have put an end to the golden era of biotech stocks. Read More STAT+: Hospitals say peak labor costs are behind them By Bob Herman Bob Herman/STAT Rising labor costs has been the main financial concern for hospitals over the past year, but those costs have peaked and are now a lot lower. Read More The pandemic showed the power of viral sequencing. Now the U.K. plans to decode other respiratory bugs By Andrew Joseph General Photographic Agency/Getty Images A new program will track the genomes of other coronaviruses, flus, RSV, and other pathogens that cause waves of illness every year. Read More STAT+: Illumina, the DNA sequencing giant, gives Wall Street bad news By Matthew Herper Adobe Illumina said its consolidated earnings per share would be in the range of $1.25, dramatically below the expected $2.99 per share. Read More Tuesday, January 10, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser